These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 28673384

  • 1. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV.
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [Abstract] [Full Text] [Related]

  • 2. MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial.
    Magnussen LV, Andersen PE, Diaz A, Ostojic J, Højlund K, Hougaard DM, Christensen AN, Nielsen TL, Andersen M.
    Eur J Endocrinol; 2017 Aug; 177(2):157-168. PubMed ID: 28522646
    [Abstract] [Full Text] [Related]

  • 3. Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy.
    Magnussen LV, Glintborg D, Hermann P, Hougaard DM, Højlund K, Andersen M.
    Diabetes Obes Metab; 2016 Oct; 18(10):980-9. PubMed ID: 27265844
    [Abstract] [Full Text] [Related]

  • 4. Testosterone therapy preserves muscle strength and power in aging men with type 2 diabetes-a randomized controlled trial.
    Magnussen LV, Hvid LG, Hermann AP, Hougaard DM, Gram B, Caserotti P, Andersen MS.
    Andrology; 2017 Sep; 5(5):946-953. PubMed ID: 28914503
    [Abstract] [Full Text] [Related]

  • 5. Mitochondria, glycogen, and lipid droplets in skeletal muscle during testosterone treatment and strength training: a randomized, double-blinded, placebo-controlled trial.
    Jensen RC, Christensen LL, Nielsen J, Schrøder HD, Kvorning T, Gejl K, Højlund K, Glintborg D, Andersen M.
    Andrology; 2018 Jul; 6(4):547-555. PubMed ID: 29656500
    [Abstract] [Full Text] [Related]

  • 6. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors.
    Hackett G, Cole N, Mulay A, Strange RC, Ramachandran S.
    BJU Int; 2019 Mar; 123(3):519-529. PubMed ID: 30216622
    [Abstract] [Full Text] [Related]

  • 7. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.
    Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):139-46. PubMed ID: 17940111
    [Abstract] [Full Text] [Related]

  • 8. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports.
    Saad F, Yassin A, Almehmadi Y, Doros G, Gooren L.
    Aging Male; 2015 Jan; 18(3):164-8. PubMed ID: 26075537
    [Abstract] [Full Text] [Related]

  • 9. Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men.
    Fink J, Matsumoto M, Tamura Y.
    Steroids; 2018 Oct; 138():161-166. PubMed ID: 30118780
    [Abstract] [Full Text] [Related]

  • 10. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
    Borst SE, Yarrow JF.
    Am J Physiol Endocrinol Metab; 2015 Jun 15; 308(12):E1035-42. PubMed ID: 25898953
    [Abstract] [Full Text] [Related]

  • 11. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men.
    Frederiksen L, Højlund K, Hougaard DM, Mosbech TH, Larsen R, Flyvbjerg A, Frystyk J, Brixen K, Andersen M.
    Eur J Endocrinol; 2012 Mar 15; 166(3):469-76. PubMed ID: 22190001
    [Abstract] [Full Text] [Related]

  • 12. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes.
    Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH.
    Eur J Endocrinol; 2007 May 15; 156(5):595-602. PubMed ID: 17468196
    [Abstract] [Full Text] [Related]

  • 13. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
    Kapoor D, Goodwin E, Channer KS, Jones TH.
    Eur J Endocrinol; 2006 Jun 15; 154(6):899-906. PubMed ID: 16728551
    [Abstract] [Full Text] [Related]

  • 14. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial.
    Glintborg D, Vaegter HB, Christensen LL, Bendix E, Graven-Nielsen T, Andersen PG, Andersen M.
    Eur J Endocrinol; 2020 Jun 15; 182(6):539-548. PubMed ID: 32213659
    [Abstract] [Full Text] [Related]

  • 15. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.
    Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, Green K, Makdissi A, Hejna J, Chaudhuri A, Punyanitya M, Dandona P.
    Diabetes Care; 2016 Jan 15; 39(1):82-91. PubMed ID: 26622051
    [Abstract] [Full Text] [Related]

  • 16. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity.
    Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, Shikuma CM, AIDS Clinical Trials Group Protocol A5079 Study Team.
    J Clin Endocrinol Metab; 2007 Mar 15; 92(3):1049-57. PubMed ID: 17164307
    [Abstract] [Full Text] [Related]

  • 17. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS.
    JAMA; 2006 Nov 15; 296(19):2351-61. PubMed ID: 17105798
    [Abstract] [Full Text] [Related]

  • 18. MYTHS AND CONTROVERSIES IN HYPOGONADISM TREATMENT OF AGING MALES.
    Ungureanu MC, Costache II, Preda C, Mogoş V, Vulpoi C, Leuştean L.
    Rev Med Chir Soc Med Nat Iasi; 2015 Nov 15; 119(2):325-33. PubMed ID: 26204632
    [Abstract] [Full Text] [Related]

  • 19. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
    Wu XY, Mao JF, Lu SY, Zhang Q, Shi YF.
    Chin Med J (Engl); 2009 Dec 05; 122(23):2846-50. PubMed ID: 20092788
    [Abstract] [Full Text] [Related]

  • 20. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.
    Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL.
    J Clin Endocrinol Metab; 2005 Mar 05; 90(3):1502-10. PubMed ID: 15572415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.